Search

Your search keyword '"Ziada, Khaled M."' showing total 395 results
Start Over Author "Ziada, Khaled M."
395 results on '"Ziada, Khaled M."'

101. Open Wide

Author

Leung, Steve W., primary, Gurley, John C., additional, Ziada, Khaled M., additional, Reda, Hassan K., additional, Smith, Mikel D., additional, and Sorrell, Vincent L., additional

Published
2014
Full Text
View/download PDF

102. Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar

Author

Dery, Jean-Pierre P., Mahaffey, Kenneth, Tricoci, Pierluigi, White, Harvey, Podder, Mohua, Moliterno, David, Harrington, Robert, Chen, Edmond, Strony, John, Van de Werf, Frans, Ziada, Khaled M., Held, Claes, Aylward, Philip, Armstrong, Paul W., Rao, Sunil, Dery, Jean-Pierre P., Mahaffey, Kenneth, Tricoci, Pierluigi, White, Harvey, Podder, Mohua, Moliterno, David, Harrington, Robert, Chen, Edmond, Strony, John, Van de Werf, Frans, Ziada, Khaled M., Held, Claes, Aylward, Philip, Armstrong, Paul W., and Rao, Sunil

Published
2013

103. Contributors

Author

Abraham, William T., Agarwal, Shikhar, Ahn, Jung-Min, Akasaka, Takashi, Akin, Ibrahim, Alcivar-Franco, Diego, Allen, Scott F., Almonacid, Alexandra, Alviar, Carlos L., Andalib, Ali, Angiolillo, Dominick J., Ansel, Gary M., Balter, Stephen, Balzer, David T., Barsness, Gregory W., Beekman, Robert H., III, Bertrand, Olivier F., Beygui, Farzin, Bittl, John A., Brindis, Ralph, Brochet, Eric, Buller, Christopher, Büttner, Heinz Joachim, Byrne, Robert A., Byrnes, Timothy, Casserly, Ivan P., Chacko, Matthews, Chew, Derek P., Cho, Leslie, Colombo, Antonio, Costa, Marco A., Cribier, Alain, Cura, Fernando, Czarny, Matthew, Daehnert, Ingo, Dehmer, Gregory J., Delcour, Kimberly S., Dieter, Robert S., Douglas, John S., Jr., Eltchaninoff, Helene, Eng, Marvin H., Fanari, Zaher, Farooq, Vasim, Fetterly, Kenneth, Fitzgerald, Peter J., Fudim, Marat, Fuster, Valentin, Garcia, Mario J., Garg, Scot, Gencer, Baris, Goldstein, Bryan, Goldstein, Jeffrey A., Gonna, Hanney, Goswami, Nilesh J., Gray, William A., Guagliumi, Giulio, Hartshorne, Trent, Hasan, Rani, Henry, Timothy D., Herrmann, Howard C., Himbert, Dominique, Hirsch, Russel, Holmes, David R., Jr., Honda, Yasuhiro, Iqbal, Javaid, Iung, Bernard, Jneid, Hani, Jollis, James G., Jolly, Michael A., Kandzari, David E., Kapadia, Samir R., Kastrati, Adnan, Kereiakes, Dean J., Kern, Morton J., Kirtane, Ajay J., Krishnaswamy, Amar, Kubo, Takashi, Lasala, John, Lilly, Scott M., Lim, Michael J., Lombardi, William L., Lurz, Philipp C., Luu, Jane T., Meier, Bernhard, Messerli, Adrian W., Montalescot, Gilles, Moreno, Pedro R., Moses, Jeffery W., Mukherjee, Debabrata, Naderi, Sahar, Naidu, Srihari S., Nallamothu, Brahmajee K., Narins, Craig R., Ndrepepa, Gjin, Neumann, Franz-Josef, Nienaber, Christoph A., Palacios, Igor F., Palmerini, Tullio, Park, Seung-Jung, Patel, Manesh R., Patel, Uptal D., Penn, Marc S., Philip, Femi, Popma, Jeffrey J., Price, Matthew J., Rajagopal, Vivek, Rao, Sunil V., Ray, Kausik K., Reiss, G. Russell, Roffi, Marco, Rogers, R. Kevin, Sanon, Saurabh, Sanz, Javier, Scheller, Bruno, Schömig, Albert, Schueler, Beth, Serruys, Patrick W., Shishehbor, Mehdi, Shreenivas, Satya S., Silver, Kevin, Silver, Mitchell J., Simon, Daniel I., Sirbu, Vasile, Sobotka, Paul A., Stankovic, Goran, Stinis, Curtiss T., Stone, Gregg W., Suk, David, Swaminath, Deephak, Teirstein, Paul S., Topaz, On, Vahanian, Alec, Valderrábano, Miguel, Vasquez, Andres F., Vora, Amit N., Wagner, Robert, Weintraub, William S., Weiss, Sandra, White, Christopher J., Whiteside, Wendy, Williams, Mathew R., Yock, Paul G., Zajarias, Alan, Zampi, Jeffrey, Ziada, Khaled M., Zidar, David A., and Ziskind, Andrew A.

Published
2016
Full Text
View/download PDF

104. List of Contributors

Author

Abou-Chebl, Alex, Abtahian, Farhad, Agarwal, Shikhar, Alfonso, Fernando, AlMahameed, Amjad T., Anwaruddin, Saif, Baber, Usman, Banerjee, Subhash, Bangalore, Sripal, Bavry, Anthony A., Bertog, Stefan C., Bhatt, Deepak L., Bittl, John A., Brilakis, Emmanouil S., Byrne, Robert A., Cecil, Robert, Christodoulidis, Georgios, Colombo, Antonio, Doshi, Darshan, Drexel, Todd, Faxon, David P., Gafoor, Sameer, Généreux, Philippe, Goel, Sachin S., Gray, William A., Herrmann, Howard C., Heupler, Frederick A., Jr., Hofmann, Ilona, Id, Dani, Jang, Ik-Kyung, Jneid, Hani, Joner, Michael, Jumean, Marwan F., Kandzari, David E., Kapadia, Samir R., Kapur, Navin K., Kastrati, Adnan, Kern, Morton J., Kinlay, Scott, Kodali, Susheel K., Krishnaswamy, Amar, Latib, Azeem, Leon, Martin B., Margey, Ronan, Mehran, Roxana, Nanjundappa, Aravinda, O'Neill, Brian P., O'Neill, William W., Palacios, Igor F., Prieto, Lourdes R., Reinartz, Markus, Rhodes, John F., Jr., Shammas, Nicolas W., Shkumat, Nicholas, Sievert, Horst, Sista, Akhilesh K., Stone, Gregg W., Tuzcu, E. Murat, Vaskelyte, Laura, Vedantham, Suresh, White, Christopher J., Whitlow, Patrick L., Williams, David O., Wunderle, Kevin, Young, James B., and Ziada, Khaled M.

Published
2016
Full Text
View/download PDF

106. Bioactive Lipids and Cationic Antimicrobial Peptides as New Potential Regulators for Trafficking of Bone Marrow-Derived Stem Cells in Patients with Acute Myocardial Infarction

Author

Karapetyan, Anush V., primary, Klyachkin, Yuri M., additional, Selim, Samy, additional, Sunkara, Manjula, additional, Ziada, Khaled M., additional, Cohen, Donald A., additional, Zuba-Surma, Ewa K., additional, Ratajczak, Janina, additional, Smyth, Susan S., additional, Ratajczak, Mariusz Z., additional, Morris, Andrew J., additional, and Abdel-Latif, Ahmed, additional

Published
2013
Full Text
View/download PDF

108. Long-Term Outcomes and Causes of Death in Patients With Renovascular Disease Undergoing Renal Artery Stenting.

Author

Wallace, Eric L., Tasan, Ediz, Cook, Bryon S., Charnigo, Richard, Abdel-Latif, Ahmed K., and Ziada, Khaled M.

Subjects
RENAL artery, ACADEMIC medical centers, VASCULAR diseases, CONFIDENCE intervals, CAUSES of death, KIDNEY diseases, EVALUATION of medical care, SURGICAL stents, SURVIVAL analysis (Biometry), SURVIVAL, PROPORTIONAL hazards models, DATA analysis software, DESCRIPTIVE statistics, KAPLAN-Meier estimator, DISEASE complications, SURGERY
Abstract

Renovascular disease (RVD) can lead to hypertension and chronic kidney disease (CKD). Patients with advanced peripheral arterial disease (PAD) have a 5-year mortality of ∼30%. Rate and causes of death in patients with significant RVD, who share similar risk factors with patients having PAD, are not well defined. We assessed consecutive patients with RVD who underwent renal artery stenting at our institution over 6 years. Specific causes of death were ascertained, and the probability of survival was estimated. Cox models were fit to identify predictors of outcomes. We identified 281 patients with RVD who underwent renal stenting. Follow-up was available for all patients (median 5.1 years). All-cause mortality was 24.2% at 5 years and 33.7% at 7 years (compounded annualized death rate: 5.5%). Of the 68 deaths, 36 (52.9%) were cardiovascular (13.2% acute myocardial infarction, 13.2% stroke, 11.8% sudden death, and 10.3% congestive heart failure) and 32 (47.1%) deaths had noncardiovascular causes. In patients with RVD undergoing stenting, cardiovascular events are the most common causes of death. Compared to patients with advanced PAD, RVD may have a lower 5-year mortality. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

116. Intravascular Ultrasound Evidence of Angiographically Silent Progression in Coronary Atherosclerosis Predicts Long-Term Morbidity and Mortality After Cardiac Transplantation

Author

Tuzcu, E. Murat, primary, Kapadia, Samir R., additional, Sachar, Ravish, additional, Ziada, Khaled M., additional, Crowe, Timothy D., additional, Feng, Jingyuan, additional, Magyar, William A., additional, Hobbs, Robert E., additional, Starling, Randall C., additional, Young, James B., additional, McCarthy, Patrick, additional, and Nissen, Steven E., additional

Published
2005
Full Text
View/download PDF

117. Feasibility of simultaneous bilateral carotid artery stenting

Author

Chen, Michael S., primary, Bhatt, Deepak L., additional, Mukherjee, Debabrata, additional, Chan, Albert W., additional, Roffi, Marco, additional, Kapadia, Samir R., additional, Ziada, Khaled M., additional, Chew, Derek P., additional, Bajzer, Christopher T., additional, and Yadav, Jay S., additional

Published
2004
Full Text
View/download PDF

119. Early constriction or expansion of the external elastic membrane area determines the late remodeling response and cumulative lumen loss in transplant vasculopathy: an intravascular ultrasound study with 4-year follow-up

Author

Tsutsui, Hiroshi, primary, Schoenhagen, Paul, additional, Ziada, Khaled M, additional, Crowe, Timothy D, additional, Klingensmith, Jon D, additional, Vince, D.Geoffrey, additional, Bott-Silverman, Corinne, additional, Starling, Randall, additional, Hobbs, Robert E, additional, Young, James, additional, Nissen, Steven E, additional, and Tuzcu, E.Murat, additional

Published
2003
Full Text
View/download PDF

122. Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts

Author

Roffi, Marco, primary, Mukherjee, Debabrata, additional, Chew, Derek P., additional, Bhatt, Deepak L., additional, Cho, Leslie, additional, Robbins, Mark A., additional, Ziada, Khaled M., additional, Brennan, Danielle M., additional, Ellis, Stephen G., additional, and Topol, Eric J., additional

Published
2002
Full Text
View/download PDF

128. Lumen Loss in Transplant Coronary Artery Disease Is a Biphasic Process Involving Early Intimal Thickening and Late Constrictive Remodeling

Author

Tsutsui, Hiroshi, primary, Ziada, Khaled M., additional, Schoenhagen, Paul, additional, Iyisoy, Atila, additional, Magyar, William A., additional, Crowe, Timothy D., additional, Klingensmith, Jon D., additional, Vince, D. Geoffrey, additional, Rincon, Gustavo, additional, Hobbs, Robert E., additional, Yamagishi, Masakazu, additional, Nissen, Steven E., additional, and Tuzcu, E. Murat, additional

Published
2001
Full Text
View/download PDF

132. Pronounced Benefit of Coronary Stenting and Adjunctive Platelet Glycoprotein IIb/IIIa Inhibition in Complex Atherosclerotic Lesions

Author

Cura, Fernando A., primary, Bhatt, Deepak L., additional, Lincoff, A. Michael, additional, Kapadia, Samir R., additional, L’Allier, Philippe L., additional, Ziada, Khaled M., additional, Wolski, Katherine E., additional, Moliterno, David J., additional, Brener, Sorin J., additional, Ellis, Stephen G., additional, and Topol, Eric J., additional

Published
2000
Full Text
View/download PDF

141. Nonrenal Complications of Contrast Media

Author

Marycz, Damien and Ziada, Khaled M.

Abstract

Nonrenal complications of contrast media are caused by chemotoxic or anaphylactoid reactions related to the contrast agent used. Chemotoxicity is mainly attributed to ionic concentration and osmolality. Anaphylactoid reactions are typically caused by direct activation of basophils, mast cells, and complement rather than an observable antigen-antibody interaction, and may be acute or delayed. History of an adverse reaction following prior exposure is the strongest predictor of a subsequent adverse reaction to contrast. Premedication regimens of corticosteroids or antihistamines can lower the risk of repeat adverse reactions. Treatment of anaphylactoid reactions depends on the severity of symptoms.

Published
2014
Full Text
View/download PDF

142. Intravascular ultrasound assessment of the prevalence and causes of angiographic `haziness'...

Author

Ziada, Khaled M. and Tuzco, E. Murat

Subjects
*COMPLICATIONS of cardiac surgery
Abstract

Examines the prevalence and etiology of persistent haziness in patients undergoing ultrasound-guided high-pressure coronary stent deployment. Identification of the causes of haziness by intravascular ultrasound; Attribution of haziness to angiographically occult dissections; Echolucent soft plaques in patients with haziness due to dissections.

Published
1997
Full Text
View/download PDF

143. Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions A Systematic Review and Meta-Analysis

Author

Wiisanen, Matthew E., Abdel-Latif, Ahmed, Mukherjee, Debabrata, and Ziada, Khaled M.

Subjects
meta-analysis, bare-metal stent(s), saphenous vein graft, percutaneous coronary intervention, cardiovascular diseases, drug-eluting stent(s)
Abstract

ObjectivesWe sought to review the published data and perform a meta-analysis to reach robust conclusions in the comparison between bare-metal stents (BMS) and drug-eluting stents (DES) in saphenous vein graft (SVG) percutaneous coronary interventions (PCIs).BackgroundDrug-eluting stents are superior to BMS in reducing major adverse cardiac events (MACE) after PCI in native coronary arteries. However, studies comparing BMS with DES in PCI of SVG have had mixed results, probably due to smaller numbers and the nonrandomized nature of most of them.MethodsThe published reports search identified 4 randomized controlled trials and 19 cohort studies comparing BMS with DES in SVG interventions. Clinical end point data were abstracted and analyzed in aggregate and in subgroup analyses with random-effects model.ResultsPatients receiving DES had a lower risk of mortality (odds ratio [OR]: 0.75; confidence interval [CI]: 0.59 to 0.96), target lesion revascularization (TLR) (OR: 0.57; CI: 0.40 to 0.82), target vessel revascularization (TVR) (OR: 0.56; CI: 0.40 to 0.77), and MACE (OR: 0.61; CI: 0.42 to 0.79). Drug-eluting stent use resulted in a significant absolute risk reduction in TLR (−0.07; CI: −0.11 to −0.03), TVR (−0.10; CI: −0.15 to −0.05), and MACE (−0.12; CI: −0.18 to −0.06). There was no significant difference between the groups in recurrent myocardial infarction (OR: 0.99; CI: 0.65 to 1.51) or stent thrombosis (OR: 0.78; CI: 0.40 to 1.52).ConclusionsIn this meta-analysis comparing DES with BMS use in PCI of SVG lesions, DES use was associated with improved mortality, MACE, TLR, and TVR. There was no evidence of increased risk of myocardial infarction or stent thrombosis.

Full Text
View/download PDF

145. Catheterization Laboratory Activation Time in Patients Transferred With ST-Segment-Elevation Myocardial Infarction: Insights From the Mission: Lifeline STEMI Accelerator-2 Project.

Author

Zeitouni, Michel, Al-Khalidi, Hussein R., Roettig, Mayme L., Bolles, Michele M., Doerfler, Shannon M., Fordyce, Christopher B., Hellkamp, Anne S., Henry, Timothy D., Magdon-Ismail, Zainab, Monk, Lisa, Nelson, R. Darrell, O'Brien, Peter K., Wilson, B. Hadley, Ziada, Khaled M., Granger, Christopher B., and Jollis, James G.

Abstract

Background: Catheterization laboratory (cath lab) activation time is a newly available process measure for patients with ST-segment-elevation myocardial infarction requiring inter-hospital transfers for primary percutaneous coronary intervention that reflects inter-facility communication and urgent mobilization of interventional laboratory resources. Our aim was to determine whether faster activation is associated with improved reperfusion time and outcomes in the American Heart Association Mission: Lifeline Accelerator-2 Project.Methods and Results: From April 2015 to March 2017, treatment times of 2063 patients with ST-segment-elevation myocardial infarction requiring inter-hospital transfer for primary percutaneous coronary intervention from 12 regions around the United States were stratified by cath lab activation time (first hospital arrival to cath lab activation within [timely] or beyond 20 minutes [delayed]). Median cath lab activation time was 26 minutes, with a delayed activation observed in 1241 (60.2%) patients. Prior cardiovascular or cerebrovascular disease, arterial hypotension at admission, and black or Latino ethnicity were independent factors of delayed cath lab activation. Timely cath lab activation patients had shorter door-in door-out times (40 versus 68 minutes) and reperfusion times (98 versus 135 minutes) with 80.1% treated within the national goal of ≤120 minutes versus 39.0% in the delayed group.Conclusions: Cath lab activation within 20 minutes across a geographically diverse group of hospitals was associated with performing primary percutaneous coronary intervention within the national goal of ≤120 minutes in >75% of patients. While several confounding factors were associated with delayed activation, this work suggests that this process measure has the potential to direct resources and practices to more timely treatment of patients requiring inter-hospital transfer for primary percutaneous coronary intervention. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

147. Revascularization Strategies for Non-ST-Elevation Myocardial Infarction.

Author

George, Bennet, Misumida, Naoki, and Ziada, Khaled M.

Abstract

Purpose of Review: Non-ST-elevation myocardial infarction (NSTEMI) is an urgent medical condition that requires prompt application of simultaneous pharmacologic and non-pharmacologic therapies. The variation in patient clinical characteristics coupled with the multitude of treatment modalities makes optimal and timely management challenging. This review summarizes risk stratification of patients, the role and timing of revascularization, and highlights important considerations in the revascularization approach with attention to individual patient characteristics. Recent Findings: The early invasive management of NSTEMI has fostered a reduction in future ischemic events. Risk calculators are helpful in determining which patients should receive early invasive management. As many patients have multivessel disease, identifying the true culprit lesion can be challenging. Special attention should be given to those at the highest risk, such as diabetics, patients with renal failure, and those with left main disease. Summary: In patients with acute coronary syndrome, the decision and mode of revascularization should carefully integrate the patient's clinical characteristics as well as the complexity of the coronary anatomy. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

150. Abstract 16433: Systemic Inflammation Predicts Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction

Author

Aboaly, Mohamed, Chelvarajan, Lakshman, Sexton, Travis R, Thompson, Mindy, Smyth, Susan S, Ziada, Khaled M, and Abdel-latif, Ahmed

Abstract

Introduction:Systemic inflammation is well documented after ST-elevation myocardial infarction (STEMI), however, its clinical significance is not fully understood.Methods:We recruited 57 STEMI patients who underwent primary percutaneous coronary intervention (PPCI) and were followed for a median follow-up of 15 months. Blood samples were obtained before PPCI (BSL) then at 3 hours, 6 hours, 12 hours, and 24 hours. Circulating inflammatory cells and their subtypes were quantified using flow cytometry. Simultaneously, plasma cytokine levels were quantified using multiplex cytokine assay. Our primary endpoint was a composite of recurrent MI, revascularization, hospitalization for heart failure, stent thrombosis, in-stent restenosis, or all-cause death. The risk of developing clinical outcomes was explored using multivariable cox proportional hazards regression model.Results:After adjusting for clinical confounding factors including age, patient comorbidities and revascularization success and timing, patients with high levels (above the median) of circulating inflammatory cells and cytokines were at an increased risk of experiencing the primary endpoint in comparison to patients with lower levels (? median): adjusted hazards ratio (aHR) for Macrophage inflammatory protein 1-alpha (MIP1-?): aHR 14.7, 95% CI 0.92 - 236.5, p=0.05, classical monocytes/CD11b+: aHR 4.5, 95% CI 0.81 - 25.23, p=0.08, CD11b+ Granulocytes: aHR 5.2, 95% CI 0.86 - 31.41, p=0.07, and Granulocyte-platelet aggregates: aHR 6.0, 95% CI 1.1 - 32.4, p=0.03 (Figure).Conclusion:This study confirms that multiple markers of inflammation are independently associated with higher risk of adverse clinical outcomes among patients with acute myocardial infarction. Incorporating these markers along with verified clinical parameters in a comprehensive risk assessment tool can help guide therapy for patients with STEMI.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results